Subsection
Cardiovascular Health sits under Chronic Condition Management . Heart and vascular disease: risk, diagnosis, and the evidence behind treatment.
8 stories
Novartis discontinues pelacarsen after Phase 3 trial showed no cardiovascular benefit. Learn why this Lp(a)-lowering drug failed and what novel RNA therapies are coming next.
A small CRISPR Therapeutics trial dropped LDL by roughly 50 percent with a single infusion, and the effect held for a full year. Here is how in-body gene editing differs from statins, enlicitide, and inclisiran, who could qualify, and what the long-term unknowns are.
Direct oral anticoagulants (DOACs) replaced warfarin for many people with atrial fibrillation. We explain why DOACs need less monitoring, how they compare on stroke and bleeding, and who still needs warfarin.
Inconsistent home BP readings often trace to device choice and technique, not your health. Here is how to pick a validated cuff and measure like a clinician.
Enlicitide (Lipfendra), the first oral PCSK9 inhibitor, won FDA approval in July 2026 and cuts LDL by more than half. Here is who it helps and how it fits with statins.
The 2026 ACC/AHA dyslipidemia guideline says every adult should be tested once for Lp(a), adds ApoB and 30-year risk, and brings back specific LDL targets. Here is what the changes mean for you.
The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 recommendations with earlier screening, new PREVENT risk equations, universal Lp(a) testing, and lower LDL-C targets for many patients.
The AHA and ACC issued the first clinical guideline for cardiovascular-kidney-metabolic syndrome in June 2026. Here is what the four-stage system means for your care.
More from Chronic Condition Management .
